-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
14,824 Shares in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Bought by Spartan Fund Management Inc.
14,824 Shares in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Bought by Spartan Fund Management Inc.
Spartan Fund Management Inc. acquired a new position in shares of DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,824 shares of the company's stock, valued at approximately $181,000. Spartan Fund Management Inc. owned about 0.06% of DA32 Life Science Tech Acquisition at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the business. Exos Asset Management LLC raised its holdings in DA32 Life Science Tech Acquisition by 4.6% during the first quarter. Exos Asset Management LLC now owns 76,951 shares of the company's stock worth $748,000 after buying an additional 3,402 shares during the last quarter. Ursa Fund Management LLC acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $243,000. Piper Sandler & CO. acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $244,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $486,000. Finally, Fir Tree Capital Management LP acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $758,000. Institutional investors and hedge funds own 60.43% of the company's stock.
Get DA32 Life Science Tech Acquisition alerts:DA32 Life Science Tech Acquisition Stock Performance
DALS opened at $9.74 on Friday. The company's fifty day moving average price is $9.72 and its two-hundred day moving average price is $9.71. DA32 Life Science Tech Acquisition Corp. has a 1-year low of $9.58 and a 1-year high of $10.26.
About DA32 Life Science Tech Acquisition
(Get Rating)DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
See Also
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Spartan Fund Management Inc. acquired a new position in shares of DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,824 shares of the company's stock, valued at approximately $181,000. Spartan Fund Management Inc. owned about 0.06% of DA32 Life Science Tech Acquisition at the end of the most recent quarter.
根據斯巴達基金管理公司在最近提交給美國證券交易委員會(美國證券交易委員會)的13F文件中所述,該公司在第一季度收購了DA32生命科學技術收購公司(DA32生命科學技術收購公司)的新股票頭寸。該機構投資者購買了14,824股該公司股票,價值約181,000美元。截至最近一個季度末,斯巴達基金管理公司持有DA32 Life Science Tech收購約0.06%的股份。
Several other institutional investors have also recently bought and sold shares of the business. Exos Asset Management LLC raised its holdings in DA32 Life Science Tech Acquisition by 4.6% during the first quarter. Exos Asset Management LLC now owns 76,951 shares of the company's stock worth $748,000 after buying an additional 3,402 shares during the last quarter. Ursa Fund Management LLC acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $243,000. Piper Sandler & CO. acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $244,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $486,000. Finally, Fir Tree Capital Management LP acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $758,000. Institutional investors and hedge funds own 60.43% of the company's stock.
其他幾家機構投資者最近也買賣了該公司的股票。EXOS Asset Management LLC在第一季度將其在DA32生命科學技術收購中的持股增加了4.6%。EXOS Asset Management LLC現在持有76,951股該公司股票,價值748,000美元,上個季度又購買了3,402股。Ursa Fund Management LLC在第一季度收購了DA32生命科學技術公司,價值243,000美元。派珀·桑德勒公司在第一季度收購了DA32生命科學技術公司的一個新頭寸,價值244,000美元。賓夕法尼亞州聯邦公立學校Empls Retrmt Systems在第一季度收購DA32生命科學技術公司時獲得了一個新頭寸,價值486,000美元。最後,Fir Tree Capital Management LP在第一季度收購了DA32生命科學技術公司,價值75.8萬美元。機構投資者和對衝基金持有該公司60.43%的股票。
DA32 Life Science Tech Acquisition Stock Performance
DA32生命科學技術收購股票表現
DALS opened at $9.74 on Friday. The company's fifty day moving average price is $9.72 and its two-hundred day moving average price is $9.71. DA32 Life Science Tech Acquisition Corp. has a 1-year low of $9.58 and a 1-year high of $10.26.
DALS週五開盤報9.74美元。該公司的50日移動均線價格為9.72美元,200日移動均線價格為9.71美元。DA32生命科學技術收購公司的股價跌至9.58美元的一年低點和10.26美元的一年高點。
About DA32 Life Science Tech Acquisition
關於DA32生命科學技術收購
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
DA32生命科學技術收購公司沒有重大業務。它側重於與一個或多個企業進行合併、資本換股、資產收購、股票購買、重組或相關業務合併。該公司打算確定生物技術和生命科學基礎設施領域的業務合併目標。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 免費獲取StockNews.com關於DA32生命科學技術收購(DALS)的研究報告
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
- 沒有人告訴這三隻股票這是下跌的一週
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上,Arbor Realty Trust的股息值得嗎?
- 投資者應關注RF Industries
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
獲得DA32生命科學技術收購日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對DA32生命科學技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧